Human Molecular Genetics, 2001, Vol. 10, No. 10 1019-1027
© 2001 Oxford University Press
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
1Departments of Surgery, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115, USA, 2Department of Adult Oncology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02215, USA and 3Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02115, USA
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germ line mutation of the von Hippel-Lindau tumor suppressor gene (VHL). Tumors observed in this disorder include retinal and central nervous system hemangioblastomas, clear cell renal carcinomas and pheochromocytomas. The VHL gene product, pVHL, is a component of a ubiquitin ligase which targets the transcription factor known as hypoxia-inducible factor (HIF) for degradation in the presence of oxygen. pVHL also plays roles in the control of extracellular matrix formation and cell-cycle exit. Different VHL mutations confer different site-specific risks of cancer. Type 2C VHL mutations confer an increased risk of pheochromocytoma without the other stigmata of VHL disease. Here we report that the products of such type 2C VHL alleles retain the ability to down regulate HIF but are defective for promotion of fibronectin matrix assembly. Furthermore, pVHL L188V, a well studied type 2C mutant, retained the ability to suppress renal carcinoma growth in vivo. These studies strengthen the notion that HIF deregulation plays a causal role in hemangioblastoma and renal carcinoma, and raises the possibility that abnormal fibronectin matrix assembly contributes to pheochromocytoma pathogenesis in the setting of VHL disease.
+ To whom correspondence should be addressed. Tel: +1 617 632 3975; Fax: +1 617 632 4760; Email: william_kaelin@dfci.harvard.edu